Q4 2024 Egetis Therapeutics AB (publ) Earnings Call Transcript
Key Points
- Egetis Therapeutics AB (FRA:P0F) received full approval for Emcitate in Europe, marking a significant milestone for the company.
- The European Thyroid Association issued guidelines recommending Emcitate as a long-term therapy, which supports its commercialization efforts.
- New data presented at the European Thyroid Association showed that Emcitate treatment is associated with a threefold reduction in mortality risk.
- The company submitted a patent application to the US Patent and Trademark Office, potentially extending market exclusivity.
- Egetis conducted a successful directed share issue, raising approximately USD 30 million, strengthening its financial position.
- Revenues for the full year 2024 decreased compared to 2023, partly due to one-time license income in the previous year.
- The company faces complex and time-consuming pricing and reimbursement negotiations across 27 EU countries.
- There are challenges in patient recruitment for the ReTRIACt study, with some dropouts due to family circumstances.
- Operating expenses increased due to investments in commercial buildup and non-cash items, impacting financial results.
- The company does not disclose specific patient numbers per country, which may limit transparency for investors.
()-
Thank you very much, operator, and a warm welcome to EDTs quarter 4 and full year results planned for 30 minutes. For those I haven't had the privilege to meet, my name is Nicholas Svesterholm, and I am the CEO of the company.
With me today, I also have Yilmaz Mahshid, Chief Financial Officer, Henrik Kruk, our Vice President, commercial operations, and Carl Hard, head of investor relations.
Let's turn our attention to the topics to be covered today. But first, let me begin with saying that I'm very proud of the full approval of Emcitate in Europe received on the 13th of February.
This represents the single most important milestone in Egetis's history and a major step forward for the company building a sustainable rare disease business. And we are also very much delighted to bring this much needed new treatment to patients with Emcitate deficiency in Europe. It also of course marks the start of a transition for the company from late stage development company to commercial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
